Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire

Eli Lilly Isn't Replacing Zepbound -- It's Building an Obesity Empire

Key PointsEli Lilly's newer weight-loss medicines will help cement its dominance in the market.The company could ride this tailwind through the medium term and deliver strong returns. 10 stocks we like better than Eli Lilly › Eli Lilly (NYSE: LLY) currently leads the weight loss market thanks to Zepbound. Given that analysts project this area will gain significant traction in the coming years, that may provide a strong tailwind to the drugmaker.…

Lilly plans to launch Orforglipron in India: New oral GLP-1 pill for weight loss

New Delhi: US drugmaker Eli Lilly is expected to launch its oral weight‑loss pill Orforglipron in India. If introduced, it will expand access to obesity treatment. It may be noted that the drug may be launched at a time when obesity drugs are being extensively sold in India. Speaking to Moneycontrol, Winselow Tucker, President and General Manager, Eli Lilly and Company (India), said the pharmaceutical company is committed to launch orforglipron …